A novel polymorphic CAAT/enhancer-binding protein β element in the FasL gene promoter alters Fas ligand expression:: A candidate background gene in African American systemic lupus erythematosus patients

被引:186
作者
Wu, JM
Metzt, C
Xu, XL
Abe, R
Gibson, AW
Edberg, JC
Cooke, J
Xie, FL
Cooper, GS
Kimberly, TP
机构
[1] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA
[2] Picower Inst Med Res, Med Biochem Lab, Manhasset, NY 11030 USA
[3] Rush Presbyterian St Lukes Med Ctr, Dept Gen Surg, Chicago, IL 60612 USA
[4] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.4049/jimmunol.170.1.132
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A single-nucleotide polymorphism (SNP), identified at nucleotide position -844 in the 5' promoter of the FasL gene, lies within a putative binding motif for CAAT/enhancer-binding protein beta (C/EBPbeta). Electrophoretic mobility shift and supershift assays confirmed that this element binds specifically to C/EBPbeta and demonstrated that the two alleles of this element have different affinities for C/EBPbeta. In luciferase reporter assays, the -844C genotype had twice the basal activity of the -844T construct, and basal expression of Fas ligand (FasL) on peripheral blood fibrocytes was also significantly higher in -844C than in -844T homozygous donors. FasL is located on human chromosome 1q23, a region that shows linkage to the systemic lupus autoimmune phenotype. Analysis of 211 African American systemic lupus erythematosus patients revealed enrichment of the -844C homozygous genotype in these systemic lupus erythematosus patients compared with 150 ethnically matched normal controls (p = 0.024). The -844C homozygous genotype may lead to the increased expression of FasL, to altered FasL-mediated signaling in lymphocytes, and to enhanced risk for autoimmunity. This functionally significant SNP demonstrates the potential importance of SNPs in regulatory regions and suggests that differences in the regulation of FasL expression may contribute to the development of the autoimmune phenotype.
引用
收藏
页码:132 / 138
页数:7
相关论文
共 43 条
[1]  
ABE R, 2000, FASEB J, V14
[2]   A NUCLEAR FACTOR FOR IL-6 EXPRESSION (NF-IL6) IS A MEMBER OF A C/EBP FAMILY [J].
AKIRA, S ;
ISSHIKI, H ;
SUGITA, T ;
TANABE, O ;
KINOSHITA, S ;
NISHIO, Y ;
NAKAJIMA, T ;
HIRANO, T ;
KISHIMOTO, T .
EMBO JOURNAL, 1990, 9 (06) :1897-1906
[3]  
ALAM T, 1992, J BIOL CHEM, V267, P5021
[4]  
AMASAKI Y, 1995, CLIN EXP IMMUNOL, V99, P245
[5]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[6]   TH1 CD4+ LYMPHOCYTES DELETE ACTIVATED MACROPHAGES THROUGH THE FAS/APO-1 ANTIGEN PATHWAY [J].
ASHANY, D ;
SONG, X ;
LACY, E ;
NIKOLICZUGIC, J ;
FRIEDMAN, SM ;
ELKON, KB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (24) :11225-11229
[7]   CIRCULATING FIBROCYTES DEFINE A NEW LEUKOCYTE SUBPOPULATION THAT MEDIATES TISSUE-REPAIR [J].
BUCALA, R ;
SPIEGEL, LA ;
CHESNEY, J ;
HOGAN, M ;
CERAMI, A .
MOLECULAR MEDICINE, 1994, 1 (01) :71-81
[8]   The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ [J].
Chesney, J ;
Bacher, M ;
Bender, A ;
Bucala, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (12) :6307-6312
[9]  
Chesney J, 1998, J IMMUNOL, V160, P419
[10]   B cells in systemic autoimmune disease: Recent insights from Fas-deficient mice and men [J].
Elkon, KB ;
MarshakRothstein, A .
CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (06) :852-859